THBS1 and neoplasm: TPST-1120 has demonstrated multiple modes of anti-tumor action in preclinical studies in advanced solid tumors, including an inhibition of tumor proliferation, an increase in the anti-angiogenic factor thrombospondin 1, and a reduction in T cell exhaustion [161].